IL2 and neoplasm: The autologous TILs for adoptive T-cell therapy are prepared by culturing a resected tumor specimen in a high concentration of recombinant interleukin-2 (IL-2), along with IL-15 and IL-21 if necessary, then selecting and expanding them in vitro and transferring them back to the patient [49].